Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects
Type 2 Diabetes Mellitus
About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Each subject was required to meet the following criteria at the time of enrollment to be eligible for the study:
- To have been male or female adults ≥ 18 years of age.
- To have been negative on the urine pregnancy test and agreed to abstain from coitus or use contraception during the entire study if a subject was female of childbearing potential.
- To have had a diagnosis of T2DM with HbA1c levels between 7.0% and 11% (inclusive) at the time of screening.
- To have been treated with a stable dose of ≥ 1500 mg/day metformin only along with diet and exercise counseling for at least 8 weeks at the time of screening.
- To have had a BMI ≤ 45 kg per m2 at the time of screening.
- To have been taking stable doses of treatment for dyslipidemia and/or hypertension for 30 days if applicable.
- To have been willing and able to return for all clinic visits and to complete all study-required procedures.
- To have adhered to the investigational product administration requirements as evidenced by missing no more than 1 day of run-in medications.
Potential subjects who exhibited any of the following characteristics were to be excluded from the study:
- Diagnosis of type 1 diabetes mellitus or maturity-onset diabetes of the young (MODY)
- Hemoglobinopathy that affected HbA1c measurement
- Any contraindication to the safe use of DPP-4 therapy or sitagliptin, including known hypersensitivity reaction
- History of pancreatitis
- Genitourinary tract infection within 6 weeks of screening or history of ≥ 3 genitourinary infections requiring treatment within 6 months from the time of screening
- Cancer, active or in remission, for < 3 years
- History of alcohol or illicit drug abuse in the past 2 years
- Triglycerides > 500 mg dL-1 at Visit V1
- Evidence of abnormal liver function tests (total bilirubin or alkaline phosphatase > 1.5 x upper limit of normal (ULN) with the exception of isolated Gilbert's syndrome); or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULN
- Estimated GFR, as calculated by the modification of diet in renal disease study equation (MDRD), < 60 mL min-1 per 1.73 m2 at the time of screening.
- Uncontrolled hypertension (SBP > 160 mm Hg or diastolic BP > 95 mm Hg) at Visit V1
- Life expectancy < 2 years
- History of MI, unstable angina, stroke or hospitalization for heart failure within 3 months at the time of screening
- History of treatment with an investigational drug within 30 days or within 7 half-lives of the investigational drug, whichever is longer
- Previous treatment with bexagliflozin or EGT0001474 study drug
- Currently or within 3 months of taking any SGLT2 inhibitor
- Currently participating in another interventional trial
- Prior renal transplantation or evidence of nephrotic syndrome (defined as a urine albumin-to-creatinine ratio (UACR) > 1500 mg g-1 at the time of screening).
- Any condition, disease, disorder or clinically relevant abnormality that could have jeopardized the subject's appropriate participation in this study or obscure the effects of treatment
- Female subjects who were pregnant or nursing
- Two or more consecutive SMBG measures ≥ 250 mg dL-1 (13.9 mmol L-1) prior to randomization accompanied by clinical signs or symptoms of hyperglycemia prior to randomization, including weight loss, blurred vision, increased thirst increased urination, or fatigue
Sites / Locations
- Clinical Research Site 1357
- Clinical Research Site 1358
- Clinical Research Site 1361
- Clinical Research Site 1031
- Clinical Research Site 1271
- Clinical Research Site 1359
- Clinical Research Site 1009
- Clinical Research Site 1037
- Clinical Research Site 1008
- Clinical Research Site 1360
- Clinical Research Site 3119
- Clinical Research Site 3123
- Clinical Research Site 3120
- Clinical Research Site 3112
- Clinical Research Site 3122
- Clinical Research Site 9102
- Clinical Research Site 9101
- Clinical Research Site 9106
- Clinical Research Site 9107
- Clinical Research Site 9105
- Clinical Research Site 9103
- Clinical Research Site 6031
- Clinical Research Site 6037
- Clinical Research Site 6042
- Clinical Research Site 6040
- Clinical Research Site 6035
- Clinical Research Site 6034
- Clinical Research Site 6039
- Clinical Research Site 6041
- Clinical Research Site 6032
- Clinical Research Site 6036
- Clinical Research Site 6038
- Clinical Research Site 6033
- Clinical Research Site 7137
- Clinical Research Site 7144
- Clinical Research Site 7142
- Clinical Research Site 7139
- Clinical Research Site 7141
- Clinical Research Site 7120
- Clinical Research Site 7138
- Clinical Research Site 7131
- Clinical Research Site 7143
- Clinical Research Site 7140
- Clinical Research Site 7136
- Clinical Research Site 7107
- Clinical Research Site 7128
- Clinical Research Site 9002
- Clinical Research Site 9016
- Clinical Research Site 9005
- Clinical Research Site 9017
- Clinical Research Site 9013
- Clinical Research Site 9012
- Clinical Research Site 9011
- Clinical Research Site 9014
- Clinical Research Site 9015
- Clinical Research Site 9018
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Bexagliflozin
Sitagliptin
Subjects will receive a bexagliflozin tablet, 20 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for sitagliptin daily for the duration of the study.
Subjects will receive a sitagliptin tablet, 100 mg, once daily for the duration of the study. Subjects will continue taking metformin and receive placebo for bexagliflozin for the duration of the study.